英格兰和威尔士服务不足患者群体中类风湿关节炎生物制剂及靶向合成改善病情抗风湿药启动的相关因素:一项全国队列研究
该观察性队列研究基于英国国家早期炎症性关节炎审计(NEIAA)数据,纳入2018年5月8日至2022年4月30日新诊断类风湿关节炎且有12个月随访数据的6098例患者,分析12个月内启动生物制剂或靶向合成改善病情抗风湿药(DMARDs)的相关因素。结果显示启动率8.3%,<40岁患者较>65岁患者启动可能性更高(aRR 2.41),亚洲个体较白人启动可能性更低(aRR 0.52),黑人个体较白人启动可能性更高(aRR 1.54)但调整基线疾病严重度和自身抗体状态后无统计学意义。作者认为启动率随种族和年龄显著变化,需为服务不足群体提供定制信息并确保公平获得高质量照护。
要点
- 6098例新诊断类风湿关节炎患者中508例(8.3%)在12个月内启动生物制剂或靶向合成DMARDs。
- <40岁患者较>65岁患者启动生物制剂或靶向合成DMARDs的可能性更高(aRR 2.41,95%CI 1.83-3.19,p<0.0001)。
- 亚洲个体较白人启动可能性更低(aRR 0.52,95%CI 0.36-0.76,p=0.0007),该差异在亚洲女性中明显而亚洲男性中不明显。
核心结论
- 在英格兰和威尔士的全民医疗体系中,新诊断类风湿关节炎患者启动生物制剂或靶向合成DMARDs的情况随种族和年龄显著变化。
- 作者认为,本研究显示为服务不足患者群体提供定制信息并确保公平获得高质量照护的重要性,若要有效减轻健康差异,必须重新考虑一刀切的做法。
研究设计与样本
- 观察性队列研究,使用国家早期炎症性关节炎审计(NEIAA)数据集。
- 纳入2018年5月8日至2022年4月30日期间入组NEIAA且有12个月随访数据的所有类风湿关节炎患者。
- 采用改良泊松回归探讨与初次风湿科评估后12个月内启动生物制剂和靶向合成DMARDs相关的因素。
- 评估因素包括年龄、性别、种族、社会经济地位(多重剥夺指数)、吸烟状况及相关合并症(肺病、心血管疾病、癌症和抑郁)。
- NEIAA由具有类风湿关节炎亲身经历的人支持,他们参与了研究设计和结果解释。
主要发现
- NEIAA中6098例患者为新诊断类风湿关节炎且有可用随访数据;平均年龄59.2岁(SD 14.9);3912例(64.2%)为女性,2186例(35.8%)为男性。
- 6047例(99.2%)患者有可用种族数据,其中5215例(86.2%)为白人,152例(2.5%)为黑人,478例(7.9%)为亚洲人,202例(3.3%)为混合或其他种族。
- 6098例患者中508例(8.3%)在12个月内启动生物制剂和靶向合成DMARDs。
- <40岁患者较>65岁患者更可能启动生物制剂和靶向合成DMARDs(多变量校正风险比2.41[95%CI 1.83-3.19];p<0.0001)。
- 亚洲个体较白人更不可能启动生物制剂和靶向合成DMARDs(0.52[0.36-0.76];p=0.0007),在调整社会经济地位、合并症、基线疾病严重度和对传统合成DMARDs的初始反应后该差异持续存在;这些差异在亚洲女性中明显但亚洲男性中不明显。
关键数值与推荐
- 年龄<40岁较>65岁:多变量校正风险比2.41(95%CI 1.83-3.19;p<0.0001)。
- 亚洲个体较白人:风险比0.52(95%CI 0.36-0.76;p=0.0007)。
- 黑人个体较白人:风险比1.54(95%CI 1.10-2.16;p=0.012),调整基线疾病严重度和自身抗体状态后无统计学意义。
临床怎么用
- 作者认为,本研究显示为服务不足患者群体提供定制信息并确保公平获得高质量照护的重要性。
- 作者认为,若要有效减轻健康差异,必须重新考虑一刀切的做法。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Quantifying health-care inequality is essential to addressing the imbalance in outcomes attributable to age, sex, race or ethnicity, and multimorbidity. In this study, we analysed differences in the initiation of biological or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis within the universal health-care system of England and Wales, UK. METHODS: An observational cohort study was conducted using the National Early Inflammatory Arthritis Audit (NEIAA) dataset. We included all patients with rheumatoid arthritis who were enrolled in NEIAA between May 8, 2018, and April 30, 2022, and who had 12-month follow-up data available. Modified Poisson regression was used to explore factors associated with the initiation of biological and targeted synthetic DMARDs within 12 months of initial rheumatology assessment. The factors evaluated included age, sex, ethnicity, socioeconomic status (index of multiple deprivation), smoking status, and relevant comorbidities (lung disease, cardiovascular disease, cancer, and depression). NEIAA is supported by people with lived experience of rheumatoid arthritis, who contributed to study design and the interpretation of findings. FINDINGS: 6098 patients in NEIAA had new diagnoses of rheumatoid arthritis and available follow-up data. The mean age was 59·2 years (SD 14·9); 3912 (64·2%) patients were women and 2186 (35·8%) were men. 6047 (99·2%) patients had available ethnicity data, of whom 5215 (86·2%) were White, 152 (2·5%) were Black, 478 (7·9%) were Asian, and 202 (3·3%) were of mixed or other ethnicities. 508 (8·3%) of 6098 patients initiated biological and targeted synthetic DMARDs within 12 months. Patients younger than 40 years were more likely to be initiated on biological and targeted synthetic DMARDs than individuals older than 65 years (multivariable-adjusted risk ratio 2·41 [95% CI 1·83-3·19]; p<0·0001). Asian individuals were less likely to be initiated on biological and targeted synthetic DMARDs than White individuals (0·52 [0·36-0·76]; p=0·0007), which persisted after adjustment for socioeconomic status, comorbidities, baseline disease severity, and the initial response to conventional synthetic DMARDs. These differences were evident for Asian women but not Asian men. Black individuals were more likely to be initiated on biological and targeted synthetic DMARDs than White individuals (1·54 [1·10-2·16]; p=0·012), which became non-significant after adjusting for baseline disease severity and autoantibody status. INTERPRETATION: The initiation of biological and targeted synthetic DMARDs for patients with newly diagnosed rheumatoid arthritis varies markedly by ethnicity and age in the universal health-care system of England and Wales. This study demonstrates the importance of providing tailored information and ensuring equitable access to high-quality care for underserved patient groups. The one-size-fits-all approach must be reconsidered if health disparities are to be mitigated effectively. FUNDING: Sandoz UK.
引用
- Russell MD, Gibson M, Zuckerman B, et al. Factors associated with biological and targeted synthetic disease-modifying antirheumatic drug initiation for rheumatoid arthritis in underserved patient groups in England and Wales, UK: a national cohort study. Lancet Rheumatol. 2024. PMID: 39423845. doi:10.1016/S2665-9913(24)00221-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。